A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer.
A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer.
Oncotarget. 2019 Jan 22;10(7):686-687
Authors: Nucera C
PMID: 30774767 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research